Other languages Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Equities

TEVA

IL0006290147

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 08:49:47 2024-05-12 am EDT			5-day change	1st Jan Change
6,030 ^ILa	+2.73%		+15.81%	+58.06%

May. 13	Piper Sandler Adjusts Price Target on Teva Pharmaceutical Industries to $20 From $19, Maintains Overweight Rating	MT
May. 08	Sector Update: Health Care Stocks Slipping Wednesday Afternoon	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

En Direct des Marchés : Sabadell, TotalEnergies, Airbnb, ARM, Medincell, Nexi...	May. 09
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	May. 08
Teva Pharmaceutical Shares Rise After Reporting Higher Q1 Earnings, Revenue; 2024 Guidance Reaffirmed	May. 08
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	May. 08
Sector Update: Health Care	May. 08
Teva Pharmaceutical Industries Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed	May. 08
Teva Pharm Q1 profit falls short of estimates, revenue gains	May. 08
Teva Pharmaceutical Industries Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024	May. 08
HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor	May. 01
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	Apr. 30
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	Apr. 30
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	Apr. 30
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	Apr. 17
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints	Apr. 11
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China	Apr. 11
Teva Pharmaceuticals International, mAbxience Sign Licensing Deal for Oncology Biosimilar Candidate	Apr. 04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 04:41 am EST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 03:19 pm EDT